/responsibility/responsible-sourcing/supplier-sustainability
/newsroom/company-statements/amgen-reaches-settlement-with-coherus-in-trade-secrets-case-regarding-pegfilgrastim
/newsroom/company-statements/amgen-statement-on-appeals-court-decision-on-pcsk9-antibody-patents
/newsroom/company-statements/amgen-comments-for-icers-2020-value-assessment-framework
/newsroom/company-statements/amgen-response-to-icers-proposed-adaptation-of-the-icer-value-framework
/science/scientific-community-initiatives/educational-outreach-program
/science/scientific-community-initiatives/scientific-conferences-program
/about/leadership/board-of-directors
/newsroom/company-statements/amgen-response-to-icers-draft-scoping-document-on-cgrp-preventive-therapy-for-migraine
/newsroom/company-statements/amgen-comments-on-the-supreme-court-of-japan-ruling-on-pcsk9-patent-infringement-litigation
/stories/categories/responsibility
/stories/categories/leadership?count=36
/newsroom/company-statements/amgen-response-to-icers-draft-evidence-report-and-voting-questions
/responsibility/responsibility-highlights-report/reporting-and-metrics
/products/global-patient-safety/adverse-event-reporting
/newsroom/company-statements/amgen-final-summary-comments-re-icer-car-t-assesssment
/newsroom/company-statements/amgen-statement-and-response-to-icer-revised-value-framework
/products/global-patient-safety/who-we-are
/newsroom/company-statements/amgen-response-to-icers-updated-value-assessment-framework
/stories/categories/patients?count=60
/science/manufacturing/innovation
/stories/categories/people-and-culture
/science/scientific-community-initiatives/start-up-network-program
/stories/categories/science-and-innovation?count=24
/stories/categories/responsibility?count=60
/newsroom/company-statements/amgen-response-to-the-icer-draft-report-on-anabolic-therapies-for-osteoporosis
/science/manufacturing/quality
/stories/categories/people-and-culture?count=72
/products/global-patient-safety/what-we-do
/responsibility/our-approach-to-pricing-access-and-affordability/access-approaches-treatment-and-collaborations
/responsibility/responsibility-highlights-report/community
/stories/categories/people-and-culture?count=48
/newsroom/company-statements/amgen-response-to-icer-rheumatoid-arthritis-draft-evidence-report
/stories/categories/leadership?count=60
/stories/categories/patients?count=84
/responsibility/responsibility-highlights-report/our-response-to-covid-19
/responsibility/responsibility-highlights-report/forward-looking-statements
/stories/categories/responsibility?count=36
/newsroom/company-statements/amgens-comments-on-icers-price-increase-draft-protocol
/partners/suppliers/supplier-diversity
/about/leadership/scientific-advisory-boards
/responsibility/responsibility-highlights-report/workplace
/about/how-we-operate/business-ethics-and-compliance
/stories/categories/patients
/newsroom/company-statements/amgen-supports-industry-efforts-to-address-global-access-to-covid-19-vaccines
/stories/categories/science-and-innovation?count=48
/newsroom/company-statements/oklahoma-health-care-authority-and-amgen-enter-into-value-based-contract-for-enbrel
/stories/categories/people-and-culture?count=36
/newsroom/company-statements/amgen-statement-on-complete-response-letter-from-the-us-fda-for-abp-980
/responsibility/responsibility-highlights-report/business-ethics
/stories/categories/people-and-culture?count=60
/stories/categories/people-and-culture?count=24
/newsroom/company-statements/amgen-statement-on-the-economic-benefit-of-xgeva
/responsibility/environmental-sustainability/performance
/stories/categories/patients?count=24
/responsibility/environmental-sustainability/case-studies
/responsibility/workplace/wellness
/responsibility/diversity-and-inclusion/commitment-to-diversity-inclusion-and-belonging
/responsibility/amgen-foundation/amgen-foundation-grants
/responsibility/commitment-to-community/us-healthcare-donations
/responsibility/commitment-to-community/equipment-donations
/newsroom/company-statements/amgen-comments-on-icers-proposed-changes-to-the-2020-value-assessment-framework
/stories/categories/science-and-innovation?count=36
/stories/categories/responsibility?count=84
/stories/categories/patients?count=72
/science/scientific-community-initiatives/postdoctoral-fellows
/newsroom/company-statements/amgen-comments-on-icers-proposed-methods-adaptations-for-assessments-of-potential-cures
/stories/categories/responsibility?count=72
/about/leadership/senior-management
/newsroom/company-statements/amgens-statement-on-cost-effectiveness-of-kyprolis-compared-to-velcade
/stories/categories/science-and-innovation?count=84
/responsibility/reporting-and-metrics/stakeholder-engagement
/stories/categories/leadership?count=48
/responsibility/commitment-to-community/non-healthcare-donations-and-sponsorships
/responsibility/commitment-to-community/independent-medical-education-funding
/stories/categories/patients?count=48
/newsroom/company-statements/amgen-provides-update-on-status-of-puerto-rico-operations
/stories/categories/science-and-innovation?count=96
/responsibility/environmental-sustainability/2027-plan
/stories/categories/leadership
/newsroom/company-statements/helping-patients-understand-the-price-of-their-medicines
/newsroom/company-statements/amgen-response-in-support-of-the-2019-esc-eas-guidelines-for-the-management-of-dyslipidaemias
/newsroom/company-statements/amgen-response-in-support-of-the-2018-aha-acc-cholesterol-clinical-practice-guidelines
/stories/categories/responsibility?count=24
/stories/categories/leadership?count=24
/partners/academic-collaborations/new-requests
/science/clinical-trials/clinical-data-transparency-practices
/newsroom/company-statements/amgen-response-to-icer-plaque-psoriasis-draft-evidence-report
/products/global-patient-safety/our-commitment
/newsroom/company-statements/amgens-response-to-icers-draft-scoping-document-on-targeted-immunomodulators-for-plaque-psoriasis
/newsroom/company-statements/amgen-statement-on-the-clinical-and-economic-value-of-blincyto
/stories/categories/patients?count=36
/newsroom/company-statements/amgen-proudly-supports-phrmas-new-principles-on-clinical-trial-diversity
/zh-tw/privacy-statement/
/stories/categories/science-and-innovation?count=60
/responsibility/reporting-and-metrics/summary-of-data
/newsroom/company-statements/amgen-reaches-settlement-agreement-to-resolve-allegations-related-to-patient-assistance-programs
/science/clinical-trials/about-clinical-trials
/newsroom/company-statements/amgens-comments-on-icer-value-based-price-of-a-cure---methods
/responsibility/reporting-and-metrics/cdp
/responsibility/corporate-responsibility-strategy-governance/amgens-commitment-to-patients
/partners/academic-collaborations/requests-for-refill-or-amendment
/newsroom/company-statements/amgen-response-to-icers-draft-scoping-document-on-car-t-therapy-for-b-cell-cancers
/newsroom/company-statements/amgen-response-to-icers--on-cgrp-inhibitors-as-preventive-treatments
/science/clinical-trials/clinical-trial-diversity
/stories/categories/science-and-innovation
/stories/categories/responsibility?count=48
/about/how-we-operate/corporate-governance
/responsibility/workplace/safety
/responsibility/reporting-and-metrics/archived-reports
/responsibility/responsibility-highlights-report/letter-from-bob-bradway
/science/clinical-trials/clinical-out-of-hours-support-program
/responsibility/our-approach-to-pricing-access-and-affordability/transformative-treatments-approaches-and-technology
/newsroom/company-statements/amgen-reponse-to-hta-program-draft-evidence-report-on-the-treatment-of-chronic-migraines
/responsibility/responsibility-highlights-report/environment
/responsibility/commitment-to-community/staff-engagement-programs
/responsibility/environmental-sustainability/sustainable-by-design
/partners/academic-collaborations/scientific-report-or-notice-of-invention
/responsibility/responsibility-highlights-report/access-to-medicine
/newsroom/company-statements/archives
/science/manufacturing/reliability
/newsroom/company-statements/amgen-introduces-new-value-based-pharmacy-benefits-insurance-provision-for-u-s--staff-members
/about/how-we-operate/policies-practices-and-disclosures
/newsroom/company-statements/amgens-position-on-orphan-drugs-and-icers-orphan-drug-assessment
/stories/categories/science-and-innovation?count=72
/c/link/
/newsroom/company-statements/amgen-statement-on-pricing
/science/clinical-trials/information-for-healthcare-professionals
/partners/suppliers/supplier-resources
/responsibility/our-approach-to-pricing-access-and-affordability/shaping-the-future-of-healthcare
/partners/academic-collaborations/submission-failed
/newsroom/company-statements/amgen-response-to-icers-call-for-comments-on-its-value-assessment-framework
/newsroom/company-statements/amgen-comments-on-pcsk9-patent-litigation-in-germany
